NCT04970836View on ClinicalTrials.gov

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

NARecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Hepatitis BVaccination; InfectionPreventable Disease, Vaccine
Interventions
BIOLOGICAL

recombinant hepatitis B vaccine

Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.

Trial Locations (1)

100

RECRUITING

Family Medicine, NTUH, Taipei

All Listed Sponsors
collaborator

Academia Sinica, Taiwan

OTHER

collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

National Taiwan University Hospital

OTHER